They mentioned that this is especially important in early breast cancer treatment; the ongoing Adjuvant Pertuzumab and Herceptin in Initial Therapy of Breast Cancer (APHINITY) trial will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.